Treatment with sunitinib alone was not inferior to nephrectomy followed by sunitinib in patients with advanced renal cell carcinoma and intermediate to high risk in effect on overall survival.
Dose-related NSAIDs with TNFi use in ankylosing spondylitis patients have a synergistic effect in slowing radiographic progression. The greatest effect is seen in those using both high-dose NSAIDs and TNFi.
In May 2018, Philips’ ICS-CERT unit released tips on the safety issues that could breach its Brilliance CT scanner. How severe and which other safety gaps are there in medical imaging systems?
At the last cardiology congress of the American Heart Association (AHA), new high blood pressure guidelines were presented. Values of 120/80 mmHg and above have been deemed high in the USA.
Vinorelbine and low-dose cyclophosphamide therapies significantly increase overall 5-year survival in high-risk children with RMS, from 73.3% without maintenance therapy to 86.5%
Infliximab, etanercept, adalimumab, ixekizumab, ustekinumab, secukinumab, and certolizumab pegol provided improvements in health assessment questionnaire-disability index scores from baseline.
Tumors with high microsatellite instability (MSI) are often associated with Lynch syndrome. Tumor patients with high MSI, and mutations in DNA mismatch repair genes should be checked for the syndrome.
Tapering csDMARDs or anti-TNF showed no significant differences in flare ratios, disease activity, functional ability and quality of life between both tapering strategies in the first 12 months of follow-up.
A study concludes that if a mean recurrence score of 11-25 is found in women with early hormone-receptor-positive HER2-negative breast carcinoma without axillary lymph nodes using a 21 gene expression test, adjuvant chemotherapy may be dispensed with.
Paris is seeing an exponential population explosion of rats. A local elected official has taken on the internet and the public to tackle the issue.
Data from the Dutch COBRA study show a normalization of rheumatoid arthritis (RA) mortality when compared to the general population after 23 years of follow-up. These findings confirm that early, intensive treatment of RA offers long-term benefits and strongly suggest these benefits include normalization of mortality.
Unprecedented 4-year survival rates can be achieved with first-line therapy in children and adolescents with T-cell Acute Lymphoblastic Leukemia (T-ALL) with the additional administration of nelarabine to COG’s augmented Berlin-Frankfurt-Münster (aBFM) chemotherapy regime.
Can conventional rheumatism drugs halve the risk of dementia in patients with rheumatoid arthritis? A large cohort study data hints at this and gives a particular protective potential for methotrexate.
In patients with Waldenström's macroglobulinemia (WM), the additional administration of ibrutinib to rituximab can reduce the risk of progression or death by relatively 80% compared to rituximab-only treatment.
Transarterial chemoembolization and external radiation therapy have been extensively investigated in combination for improved survival for this stage. However, recent trial shows that HCC patients with vascular invasion might benefit from such a combination as well.
Patients with advanced non-small cell lung cancer (NSCLC) with squamous epithelial histology may benefit from an additional dose of the PD-L1 inhibitor atezolizumab in addition to chemotherapy in first-line treatment compared to chemotherapy alone.
The number of injury-related work absences and the rising reasons behind them is raising concerns. Exoskeletons could be of help to protect a worker's health, but how secure are these complex systems?
Vitamin supplements are also widely used in many European countries. However, a US study showed that vitamins B6 and B12, taken as individual nutritional supplements, may have a role in male lung cancer incidence.
Google is a crucial bidder for Nokia Healthcare, a Nokia subdivision focusing on smart health-related products.
A recent issue of the New England Medical Journal features a study which tested two new biological agents, nivolumab, and ipilimumab, against chemotherapy in a specific population of non-small-cell lung cancer patients - those with a high tumor mutation burden (TMB).